BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35252002)

  • 41. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
    Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
    Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current management of nasal NK/T-cell lymphoma.
    Au WY
    Oncology (Williston Park); 2010 Apr; 24(4):352-8. PubMed ID: 20464847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein-Barr Virus Relation.
    Takahara M; Kumai T; Kishibe K; Nagato T; Harabuchi Y
    Microorganisms; 2021 Jun; 9(7):. PubMed ID: 34202088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation.
    Jeong SH; Song HN; Park JS; Yang DH; Koh Y; Yoon SS; Lee HW; Eom HS; Won JH; Kim WS; Kim SJ
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2471-2478. PubMed ID: 30064012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression.
    Chen Q; Feng J; Wu J; Yu Z; Zhang W; Chen Y; Yao P; Zhang H
    Leukemia; 2020 Oct; 34(10):2736-2748. PubMed ID: 32203147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma.
    Li M; Gao C; Li H; Wang Z; Cao Y; Huang W; Li X; Wang S; Yu L; Da W
    Med Oncol; 2011 Sep; 28(3):840-5. PubMed ID: 20414818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies.
    Tse E; Kwong YL
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
    Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
    Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological characteristics and treatment outcomes of cutaneous extranodal natural killer/T-cell lymphoma: a retrospective study in China.
    Chen X; Liu X; Liu W; Wang L; Zou L
    Transl Cancer Res; 2020 Oct; 9(10):6096-6106. PubMed ID: 35117221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
    Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Malignant effusions from extranodal NK/T-cell lymphomas are frequently of anaplastic morphology with azurophilic granules and of T-cell lineage.
    Liu CY; Chen BJ; Chuang SS;
    Diagn Cytopathol; 2020 May; 48(5):453-463. PubMed ID: 32020785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
    Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
    Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma.
    Cai Q; Cai J; Fang Y; Young KH
    Front Oncol; 2019; 9():386. PubMed ID: 31139570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas.
    Dubal PM; Dutta R; Vazquez A; Patel TD; Baredes S; Eloy JA
    Laryngoscope; 2015 May; 125(5):1077-83. PubMed ID: 25546466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China.
    Liang R; Wang Z; Bai QX; Gao GX; Yang L; Zhang T; Gu HT; Dong BX; Shu MM; Hao CX; Zhang N; Chen XQ
    Oncol Res Treat; 2016; 39(1-2):45-52. PubMed ID: 26891121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia.
    Kwong YL
    J Clin Exp Hematop; 2011; 51(1):21-8. PubMed ID: 21628857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages between concurrent chemoradiotherapy and sequential chemotherapy.
    Qian M; Tao H; Xu W; Ji H
    Onco Targets Ther; 2017; 10():3617-3623. PubMed ID: 28790853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cutaneous extranodal natural killer (NK) / T - cell lymphoma: A comprehensive clinical features and outcomes analysis of 71 cases.
    Jiang L; Li P; Quan Q; Chen P; Qiu H; Zhang B
    Leuk Res; 2020 Jan; 88():106284. PubMed ID: 31841860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosis and management of natural killer-cell malignancies.
    Ishida F; Kwong YL
    Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma.
    Peng YY; Xiong YY; Zhang LX; Wang J; Zhang HB; Xiao Q; Guo SL
    Turk J Haematol; 2021 Jun; 38(2):126-137. PubMed ID: 33535731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.